Global Life Science Ventures

Overview

Global Life Science Ventures (GLSV) is an independent venture capital firm focusing exclusively on the life sciences sector. Established in 1996, GLSV has offices in Munich, Germany, and Zug, Switzerland, and has advised and managed funds totaling more than €200 million. The firm is dedicated to supporting early-stage companies originating from universities, scientific institutions, or industry, and also invests in selected later-stage companies, including buy-outs. GLSV has financed 33 innovative life science companies throughout Europe and the USA, with 13 exits through IPO, trade sale, or M&A. GLSV's investment strategy emphasizes identifying companies with a leading edge in science or technology, global market potential, the ability to meet medical needs, strong intellectual property protection, and capable management teams. The firm's portfolio includes companies in pharmaceuticals, diagnostics, medical devices, and biotechnology. Notable investments include Pelikan Technologies, which developed innovative hand-held diagnostic devices for diabetes management, and IMI Intelligent Medical Implants AG, a neuro-stimulation company developing retinal implants for the blind. GLSV's approach combines finance, strategic advice, and access to expertise and international networks to foster the growth of its portfolio companies. Over the years, GLSV has built a diversified portfolio of companies in the life sciences sector, demonstrating a proven track record in identifying and nurturing innovative businesses. The firm's global perspective and commitment to the life sciences sector have established it as a significant player in the venture capital landscape, contributing to advancements in medical technologies and treatments.